◀ Back to EGF

EGF — SMC6

Text-mined interactions from Literome

Myllärniemi et al., Cardiovasc Drugs Ther 1999 : Administration of the PDGF-R tyrosine kinase inhibitor in vivo, tested and found to inhibit the proliferation of SMC induced by PDGF-AA and PDGF-BB, but not by IGF-1, EGF , or bFGF, resulted in a 60 % reduction in the absolute number and percentage of BrdU + cells after the second balloon injury to pre existing neointima, but had no significant effect on proliferation after the first injury
Mawatari et al., J Vasc Surg 2000 : The alpha v beta 3 integrin antibody also markedly inhibited TGF-1- and EGF induced SMC Fn production
Bauriedel et al., Z Kardiol 1992 (Arteriosclerosis...) : In smooth muscle cells ( SMCs ) cultured from human plaque tissue, EGF increased SMC proliferative activity in a dose dependent manner ( ED50 : 3-6 ng of EGF/ml )
Gong et al., J Biol Chem 1995 : Epidermal growth factor (EGF) or insulin-like growth factor I (IGF-I) alone had little effect on SMC ScR activity
Yamamoto et al., Exp Cell Res 1994 : We examined the effects of platelet derived growth factor ( PDGF ), insulin-like growth factor-I (IGF-I), and epidermal growth factor (EGF) on the regulation of SMC grown on type I collagen coated dishes in serum-free primary culture